These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25867268)

  • 21. Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma.
    Hang JF; Pan CC
    Pathology; 2017 Apr; 49(3):316-317. PubMed ID: 28285720
    [No Abstract]   [Full Text] [Related]  

  • 22. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.
    Siddiqui AA; Kowalski TE; Kedika R; Roy A; Loren DE; Ellsworth E; Adler D; Finkelstein SD
    Gastrointest Endosc; 2013 Apr; 77(4):669-70. PubMed ID: 23498145
    [No Abstract]   [Full Text] [Related]  

  • 23. GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct.
    Matthaei H; Wu J; Dal Molin M; Debeljak M; Lingohr P; Katabi N; Klimstra DS; Adsay NV; Eshleman JR; Schulick RD; Kinzler KW; Vogelstein B; Hruban RH; Maitra A
    HPB (Oxford); 2012 Oct; 14(10):677-83. PubMed ID: 22954004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.
    Ritterhouse LL; Vivero M; Mino-Kenudson M; Sholl LM; Iafrate AJ; Nardi V; Dong F
    Mod Pathol; 2017 Dec; 30(12):1720-1727. PubMed ID: 28776576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
    Watari J; Mitani S; Ito C; Tozawa K; Tomita T; Oshima T; Fukui H; Kadowaki S; Natsume S; Senda Y; Tajika M; Hara K; Yatabe Y; Shimizu Y; Muro K; Morimoto T; Hirota S; Das KM; Miwa H
    Sci Rep; 2019 Jul; 9(1):10526. PubMed ID: 31324814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma.
    Fu T; Guzzetta AA; Jeschke J; Vatapalli R; Dave P; Hooker CM; Morgan R; Iacobuzio-Donahue CA; Liu B; Ahuja N
    Int J Cancer; 2013 Jun; 132(11):2502-9. PubMed ID: 23065691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.
    Fecteau RE; Lutterbaugh J; Markowitz SD; Willis J; Guda K
    PLoS One; 2014; 9(1):e87966. PubMed ID: 24498230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.
    Kanda M; Matthaei H; Wu J; Hong SM; Yu J; Borges M; Hruban RH; Maitra A; Kinzler K; Vogelstein B; Goggins M
    Gastroenterology; 2012 Apr; 142(4):730-733.e9. PubMed ID: 22226782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Next-Generation Sequencing of Matched Primary and Metastatic Rectal Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to Colonic Adenocarcinomas.
    Crumley SM; Pepper KL; Phan AT; Olsen RJ; Schwartz MR; Portier BP
    Arch Pathol Lab Med; 2016 Jun; 140(6):529-35. PubMed ID: 26536055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated genetic and epigenetic analysis of cancer-related genes in non-ampullary duodenal adenomas and intramucosal adenocarcinomas.
    Ota R; Sawada T; Tsuyama S; Sasaki Y; Suzuki H; Kaizaki Y; Hasatani K; Yamamoto E; Nakanishi H; Inagaki S; Tsuji S; Yoshida N; Doyama H; Minato H; Nakamura K; Kasashima S; Kubota E; Kataoka H; Tokino T; Yao T; Minamoto T
    J Pathol; 2020 Nov; 252(3):330-342. PubMed ID: 32770675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival.
    Singhi AD; Davison JM; Choudry HA; Pingpank JF; Ahrendt SA; Holtzman MP; Zureikat AH; Zeh HJ; Ramalingam L; Mantha G; Nikiforova M; Bartlett DL; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1737-43. PubMed ID: 24925222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas.
    Hsu M; Sasaki M; Igarashi S; Sato Y; Nakanuma Y
    Cancer; 2013 May; 119(9):1669-74. PubMed ID: 23335286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors.
    Kinugasa H; Kanzaki H; Tanaka T; Yamamoto S; Yamasaki Y; Nouso K; Ichimura K; Nakagawa M; Mitsuhashi T; Okada H
    Clin Transl Gastroenterol; 2021 Nov; 12(11):e00424. PubMed ID: 34797780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct Involvement of the Sonic Hedgehog Signaling Pathway in Gastric Adenocarcinoma of Fundic Gland Type and Conventional Gastric Adenocarcinoma.
    Tajima Y; Murakami T; Saito T; Hiromoto T; Akazawa Y; Sasahara N; Mitomi H; Yao T; Watanabe S
    Digestion; 2017; 96(2):81-91. PubMed ID: 28738329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS and BRAF mutations and MSI status in precursor lesions of colorectal cancer detected by colonoscopy.
    Yamane LS; Scapulatempo-Neto C; Alvarenga L; Oliveira CZ; Berardinelli GN; Almodova E; Cunha TR; Fava G; Colaiacovo W; Melani A; Fregnani JH; Reis RM; Guimarães DP
    Oncol Rep; 2014 Oct; 32(4):1419-26. PubMed ID: 25050586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KRAS mutations in traditional serrated adenomas from Korea herald an aggressive phenotype.
    Kim KM; Lee EJ; Kim YH; Chang DK; Odze RD
    Am J Surg Pathol; 2010 May; 34(5):667-75. PubMed ID: 20305537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review.
    Tamura K; Ohtsuka T; Ideno N; Aso T; Shindo K; Aishima S; Ohuchida K; Takahata S; Ushijima Y; Ito T; Oda Y; Mizumoto K; Tanaka M
    Ann Surg; 2014 Feb; 259(2):360-8. PubMed ID: 23989056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
    Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
    Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
    Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.